Menu

News & Insights

  • Clear

AG Bonta Serves OpenAI an Investigative Subpoena, AG Raúl Torrez and Rep. Linda Serrato Announce AI Legislation

New Mexico AG Raul Torrez and State Representative Linda Serrato (D-Santa Fe) announced the Frontier Artificial Intelligence Safety and Accountability Act during Representative Serrato’s “Machines to Mesas” AI Summit. The proposed legislation requires the largest AI developers to assess and disclose the risks their models pose, backed by independent, state-authorized audits designed to catch a…

Read More

AG Torrez Leads Multistate Coalition Targeting Fast Tracking Microreactors Regulations

AG Raúl Torrez has announced that the New Mexico Department of Justice is leading a multistate coalition in submitting a letter to the U.S. Nuclear Regulatory Commission. The letter opposes a new set of regulations set by the Trump administration that would provide a fast track for licensing and deploying of nuclear microreactor technology. The coalition…

Read More

AGs Double Down in Prediction Market Battle

New Mexico AG Torrez has filed a lawsuit against Kalshi, Inc. and KalshiEX LLC. The lawsuit alleges that the company is offering online sports unlawfully in New Mexico and actively evading state gaming laws and regulations by creating an online platform that functions as a sportsbook without obtaining any gaming license from the state and…

Read More

New Mexico AG Leads Roundup of States in SCOTUS Fight

New Mexico AG Raúl Torrez led a coalition of 18 states in filing an amicus brief in support of respondent John Durnell in Monsanto Co. v. Durnell, urging the Supreme Court to reject Monsanto’s claim that federal law preempts state-law failure-to-warn suits over the herbicide Roundup. In the brief, the states argue that the Federal…

Read More

New Mexico Joins Growing List of States to Secure Insulin Price Cap Settlements

New Mexico AG Raúl Torrez announced settlements with Sanofi-Aventis U.S. LLC and Novo Nordisk Inc. to resolve allegations that the pharmaceutical companies’ pricing policies resulted in underinsured and uninsured patients paying higher prices for insulin. Under the terms of the agreements, Sanofi-Aventis and Novo Nordisk will cap the price of insulin at $35 per month for…

Read More